300143.SHE INKON Life Technology Co Ltd
- Market cap
- CNY 7.19B
- P/E
- 92.4x
- P/B
- 2.96x
- ROE
- 5.6%
- Dividend yield
- 0.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300143.SHE undervalued?
Graham numberThe Graham number of INKON Life Technology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INKON Life Technology Co Ltd fundamental analysis
No fundamental analysis for INKON Life Technology Co Ltd yet.
INKON Life Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INKON Life Technology Co Ltd
INKON Life Technology Co., Ltd. focuses on building an ecosystem platform for providing medical services for tumors in China and internationally. It provides medical devices solutions for radiotherapy, life support, image enhancement, and chronic disease treatment; and oncology medical services, as well as equipment for cancer prevention, diagnosis, treatment, and rehabilitation. The company was formerly known as Starmap Medicine and Technology Co., Ltd. and changed its name…
Full company profileINKON Life Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INKON Life Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 432M | 329M | 504M | 573M | 661M | 1.09B | 1.16B | 1.47B | 1.56B | 1.89B | 2.04B |
| Gross Profit | 174M | 187M | 229M | 229M | 223M | 261M | 307M | 416M | 403M | 511M | 571M |
| Operating Income | 63.8M | 117M | 127M | 99.3M | 84.0M | 76.5M | 119M | 166M | 157M | 231M | 245M |
| EBITDA | - | 195M | 145M | -587M | 227M | -248M | -501M | 215M | 250M | 280M | 244M |
| Net Income | 55.1M | 122M | 50.2M | -703M | 128M | -364M | -596M | 100M | 115M | 68.5M | 136M |
| EPS | - | 0.22 | 0.09 | -1.29 | 0.20 | -0.57 | -0.93 | 0.12 | 0.15 | 0.09 | 0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 2.53B | 2.61B | 2.62B | 1.96B | 2.65B | 2.47B | 2.03B | 2.40B | 3.54B | 4.19B | 4.00B |
| Total Liabilities | 338M | 178M | 555M | 590M | 410M | 668M | 711M | 971M | 1.06B | 1.58B | 1.51B |
| Shareholders' Equity | 2.16B | 2.38B | 2.04B | 1.34B | 2.21B | 1.77B | 1.28B | 1.38B | 2.43B | 2.51B | 2.42B |
| Cash & Short-term Investments | 213M | 245M | 94.0M | 96.6M | 484M | 662M | 433M | 480M | 1.24B | 1.07B | 624M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 44.6M | 167M | 99.7M | 29.8M | 84.8M | 126M | 161M | 190M | 259M | 341M | - |
| Capital Expenditure | 28.1M | 61.7M | 25.3M | 26.9M | 62.8M | 56.3M | 125M | 158M | 199M | 227M | 92.9M |
| Free Cash Flow | - | 105M | 74.4M | 2.87M | 35.4M | 69.3M | 35.3M | 31.8M | 60.6M | 114M | 443M |
| Ratios | |||||||||||
| ROE | 2.5% | 5.1% | 2.5% | -52.6% | 5.8% | -20.5% | -46.4% | 7.3% | 4.7% | 2.7% | 5.6% |
| ROA | 2.2% | 4.7% | 1.9% | -35.9% | 4.8% | -14.7% | -29.4% | 4.2% | 3.3% | 1.6% | 3.4% |
| Net Profit Margin | 12.7% | 37.2% | 10.0% | -122.8% | 19.4% | -33.4% | -51.5% | 6.8% | 7.4% | 3.6% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INKON Life Technology Co Ltd dividends
- Dividend yield
- 0.15%
- Forward dividend
- 0.03 CNY
- Payout ratio
- 15.3%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 10.5M | 0.01 | 15.3% |
| 2024 | CNY 8.62M | 0.01 | 7.5% |
| 2023 | CNY 1.26M | 0.00 | 1.3% |
| 2022 | CNY 27.7M | 0.04 | - |
| 2021 | CNY 6.75M | 0.01 | - |
| 2020 | CNY 19.7M | 0.03 | 15.4% |
| 2019 | CNY 30.1M | 0.06 | - |
| 2018 | CNY 7.43M | 0.01 | 14.8% |
| 2017 | CNY 7.43M | 0.01 | 6.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 3, 2026.
Who owns INKON Life Technology Co Ltd
- Insiders 57.78%
- Institutions 1.78%
- Public & others 40.44%
- Shares outstanding 973M
- Free float 469M
INKON Life Technology Co Ltd company profile
- Company name
- INKON Life Technology Co Ltd
- Ticker
- 300143.SHE
- ISIN
- CNE100000XF6
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 9, 2010
- Sector
- Healthcare
- Industry
- Food Products
- Employees
- 2,662
- Fiscal year end
- December
- Address
- Yingkang Yisheng Building, Qingdao, China, 266103
- Phone
- 86 53 2557 76787
- Website
- inkonlife.com
About INKON Life Technology Co Ltd
INKON Life Technology Co., Ltd. focuses on building an ecosystem platform for providing medical services for tumors in China and internationally. It provides medical devices solutions for radiotherapy, life support, image enhancement, and chronic disease treatment; and oncology medical services, as well as equipment for cancer prevention, diagnosis, treatment, and rehabilitation. The company was formerly known as Starmap Medicine and Technology Co., Ltd. and changed its name to INKON Life Technology Co., Ltd. in July 2019. INKON Life Technology Co., Ltd. was founded in 1998 and is headquartered in Qingdao, China.
INKON Life Technology Co Ltd management
5- Mr. An Jie MaGM & Director · born 1980
- Ms. Lan JiangFinancial Director · born 1981
- Mr. Zelin LiuBoard Secretary · born 1993
- Mr. Hongbo LiDeputy General Manager · born 1971
- Jinchen XieAccounting Supervisor